Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy

David Henry, Colin Dormuth, Brandace Winquist, Greg Carney, Shawn Bugden, Gary Teare, Linda E. Lévesque, Anick Bérard, J. Michael Paterson and Robert W. Platt; for the CNODES (Canadian Network for Observational Drug Effect Studies) Investigators
CMAJ July 12, 2016 188 (10) 723-730; DOI: https://doi.org/10.1503/cmaj.151243
David Henry
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: david.henry@ices.on.ca
Colin Dormuth
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brandace Winquist
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg Carney
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shawn Bugden
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Teare
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda E. Lévesque
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anick Bérard
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Michael Paterson
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert W. Platt
Institute for Clinical Evaluative Sciences (Henry, Lévesque, Paterson), Toronto, Ont.; Institute of Health Policy, Management and Evaluation (Henry), University of Toronto, Toronto, Ont.; Faculty of Medicine (Dormuth, Carney), University of British Columbia, Vancouver, BC; Saskatchewan Health Quality Council (Winquist, Teare), Saskatoon, Sask.; College of Pharmacy (Bugden), Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.; Centre for Health Services and Policy Research (Lévesque), Queen’s University, Kingston, Ont.; Faculté de pharmacie (Bérard), Université de Montréal, Montréal, Qué.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; Departments of Epidemiology and Biostatistics and of Pediatrics (Platt), McGill University, Montréal, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Metrics
  • Responses
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • Response to "Occurrence of pregnancy and pregnancy outcomes"
    Jerry KL Tan
    Posted on: 15 February 2017
  • Concerning for a Preventable teratology: isotretinoin
    R Douglas Wilson
    Posted on: 25 July 2016
  • Posted on: (15 February 2017)
    Response to "Occurrence of pregnancy and pregnancy outcomes"
    • Jerry KL Tan, Dermatologist (MD, FRCPC)
    • Other Contributors:

    In this Canadian study of pregnancies on oral isotretinoin, the finding of 3.1 pregnancies per 1000 female isotretinoin users between 1996 -2011 is cause for concern for all prescribers of this medication. The authors proffer potential reasons for inadvertent fetal exposure to oral isotretinoin including marketing of generic versions that may have lesser consumer educational resources than the original; online availabilit...

    Show More

    In this Canadian study of pregnancies on oral isotretinoin, the finding of 3.1 pregnancies per 1000 female isotretinoin users between 1996 -2011 is cause for concern for all prescribers of this medication. The authors proffer potential reasons for inadvertent fetal exposure to oral isotretinoin including marketing of generic versions that may have lesser consumer educational resources than the original; online availability without prescription or appropriate risk information; and increased utilization for milder forms of acne.1 The latter requires response from a dermatological perspective.

    The designation of clinical severity is problematic. As an illness, acne severity is multidimensional comprising primary acne lesions (type, lesion intensity, extent and distribution), scarring and psychosocial impact. However, acne guidelines typically refer to clinician assessments based on a static evaluation of primary acne lesions.2 Furthermore, acne is a chronic condition with a potential for adverse psychosocial consequences - an impact not directly correlated with clinical severity as judged by clinicians.3 Psychosocial impact may be severe despite acne being mild or moderate on clinical examination while severe acne increases the risk of attempted suicide. In patients requiring oral isotretinoin for severe acne, increased suicide risk was observed even before institution of this medication.4 Furthermore, post acne scarring is not included as a dimension in current acne severity scales. Scarring has been observed in those clinically assessed with mild-to-moderate as well as severe acne. This reflects severity fluctuation and intense inflammation leading to dermal damage. Post acne scarring is a marker for more severe acne with its own psychosocial effects and treatment consequences, typically invasive and costly.

    While oral isotretinoin has been the standard of care for severe acne,2 the management of moderate acne has evolved with increasing recognition of the public health consequences of prolonged antibiotic use. Current guidelines, recommend limiting the use of oral antibiotics to 3-4 months to mitigate this risk.5 As these agents are unlikely to lead to remssion, their discontinuation generally leads to acne recurrence and consequently, need for an alternative systemic option such as oral isotretinoin. The latter remains the sole agent with the potential for inducing remission in acne.6

    Pregnancy prevention programs have developed in parallel with the availability of oral isotretinoin in the US and Canada over the past 3 decades. In the United States, these have evolved through warning on labels; addition of red label stickers to pharmacies; addition of "avoid pregnancy" icons, patient consent forms, pregnancy testing prior to start of treatment, selection of 2 forms of birth control (Pregnancy Prevention Program or PPP, 1988); 2 pregnancy tests prior to starting treatment and pharmacist provision of a medication guide with prescriptions, dispensing limited to 30 day supply with no refills (SMART, 2001); monthly pregnancy tests, registration database for patients, prescribers, pharmacists and wholesalers, plus qualifying questions for patients and monthly identification of contraceptive methods by patients and doctors (iPLEDGE, 2006).7 Despite these increasingly stringent pregnancy risk management approaches, no significant reduction in pregnancies have been demonstrated with SMART8 or iPLEDGE9. A consequence of each, however, has been a sequential reduction in number of isotretinoin treatment courses and number of patients treated, with females being disproportionately impacted. In Canada, the current program is like PPP described above with the addition of 2 pregnancy tests prior to starting treatment and monthly pregnancy tests including one month after discontinuation.

    The conclusion of stated by the authors, that medical practitioners and female patients must be reminded of fetal risks of this medication - including adherence to pregnancy prevention program measures,1 is well founded and timely for all stakeholders. Additional considerations are the multidimensional nature of acne severity and the potential for morbidity and mortality in a subgroup of patients. The ongoing challenge with oral isotretinoin in Canada is safe and appropriate use while not limiting access to those who need it.

    References 1.Henry D, Dormuth C, Winquist B, et al. Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. CMAJ 2016;188:723-30. 2. Asai Y, Baibergenova A, Dutil M, et al. Management of acne: Canadian clinical practice guideline. CMAJ 2016;188:118-26. 3. Tan JK, Li Y, Fung K, et al. Divergence of demographic factors associated with clinical severity compared with quality of life impact in acne. J Cutan Med Surg 2008;12:235-42. 4. Sundstrom A, Alfredsson L, Sjolin-Forsberg G, et al. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010;341:c5812. 5. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:945-73. 6. Blasiak RC, Stamey CR, Burkhart CN, et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol 2013;149:1392-8. 7. Abroms L, Maibach E, Lyon-Daniel K, et al. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006;3:e483. 8. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the Accutane SMART program. Arch Dermatol 2005;141:563-9. 9. Shin J, Cheetham TC, Wong L, et al. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. J Am Acad Dermatol 2011;65:1117-25.

    Conflict of Interest:

    Dr. Jerry Tan has been an advisor, consultant and/or speaker for Cipher and Roche. Dr. Neil Shear has been an advisor, consultant and/or speaker for Cipher.

    Show Less
    Competing Interests: None declared.
  • Posted on: (25 July 2016)
    Concerning for a Preventable teratology: isotretinoin
    • R Douglas Wilson, Department Head Obstet Gynaecol

    It was very concerning to read but important that Henry D et al reported on the poor adherence to pregnancy prevention while woman are taking isotretinoin in Canada (1996-2011). This drug was first licensed in 1982 (USA) and the first reports on birth defect concerns were recognized within a year. Recommendations from the Teratology Society were first published in 1991.

    The reported risk for isotretinoin embryopathy...

    Show More

    It was very concerning to read but important that Henry D et al reported on the poor adherence to pregnancy prevention while woman are taking isotretinoin in Canada (1996-2011). This drug was first licensed in 1982 (USA) and the first reports on birth defect concerns were recognized within a year. Recommendations from the Teratology Society were first published in 1991.

    The reported risk for isotretinoin embryopathy is 35% for the embryo/fetus exposed beyond the 15th day following conception.1 The evidence supports the embryo/fetal exposure as the risk, not the use of the medication prior to conception. The embryopathy is well described with craniofacial, cardiovascular, and central nervous system (CNS) 'disruptive' anomaly patterns. Subnormal intelligence was also reported in the prospectively collected cohort of 31 intra-uterine exposed 5 year old children with 19% having a full scale IQ less than 70 and 28% having an IQ in the 71-85 range.2 The intellectual deficit was not always associated with the finding of other non-CNS major 'disruptive' anomalies as 6 of 10 children with the borderline IQ had no identified major anomalies (all children with the severe IQ deficit had other identified major anomalies).2

    This evidence point is important for the clinical use of ultrasound screening of the exposed embryo /fetus for congenital anomalies and having the conclusion of 'no anomalies , therefore not affected'.

    The Henry D et al results indicate that a much stronger message and warning is required for the appropriate pregnancy prevention knowledge transfer and counseling.The teratology messaging needs to start first with the prescribing physician and their informed consent process with the patient but in addition there needs to be stronger oversight from industry and the dispensing pharmacist (ask the question 'what birth control method will you be using while you are on this medication?').

    This teratogenic knowledge translation and prescribing process fits very clearly into the 'CHOOSING WISELY' theme. This type of teratogenic fetal exposure is entirely preventable and there is no good reason that this retinoic acid embryopathy is an acceptable pregnancy outcome while women are taking isotretinoin for appropriate medical indications, even with patient autonomy and their method of choice for pregnancy prevention.

    References:

    1. Jones KL, Jones MC, del Campo M. Retinoic Acid Embryopathy in Smith's Recognizable Patterns of Human Malformation 7th Edition 2013 Elsevier p 742-743

    2. Lammer EJ et al Risk for major malformations among fetuses exposed to isotretinoin. Teratology 1987;35:68A

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 188 (10)
CMAJ
Vol. 188, Issue 10
12 Jul 2016
  • Table of Contents
  • Index by author

Article extras

  • Podcast

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
David Henry, Colin Dormuth, Brandace Winquist, Greg Carney, Shawn Bugden, Gary Teare, Linda E. Lévesque, Anick Bérard, J. Michael Paterson, Robert W. Platt
CMAJ Jul 2016, 188 (10) 723-730; DOI: 10.1503/cmaj.151243

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
David Henry, Colin Dormuth, Brandace Winquist, Greg Carney, Shawn Bugden, Gary Teare, Linda E. Lévesque, Anick Bérard, J. Michael Paterson, Robert W. Platt
CMAJ Jul 2016, 188 (10) 723-730; DOI: 10.1503/cmaj.151243
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • A preventable teratology: isotretinoin
  • Oral isotretinoin: ensuring safe use while not limiting access to those who need it
  • PubMed
  • Google Scholar

Cited By...

  • Oral isotretinoin: ensuring safe use while not limiting access to those who need it
  • A preventable teratology: isotretinoin
  • Google Scholar

More in this TOC Section

  • Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study
  • Effectiveness of intrapartum fetal surveillance to improve maternal and neonatal outcomes: a systematic review and network meta-analysis
  • Burden of noninfluenza respiratory viral infections in adults admitted to hospital: analysis of a multiyear Canadian surveillance cohort from 2 centres
Show more Research

Similar Articles

Collections

  • Topics
    • Reproductive health, infertility & pregnancy
    • Women's health (including abortion)
    • Drugs: urogenital
    • Drugs: adverse reactions
    • Dermatology

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, CMA Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire